Tax & PenaltyJul 6, 2026, 07:02 AM
Radiopharm Receives A$5.9M R&D Tax Incentive
AI Summary
Radiopharm Theranostics Ltd announced it has received an R&D tax refund from the Australian Government for the 2025 financial year, totaling A$5,885,131, which includes A$104,475 in interest. This refund is part of Australia's R&D tax incentive program, providing a refundable tax offset of up to 43.5%. The company plans to use these funds to further develop its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications.
Key Highlights
- Radiopharm Theranostics received an R&D tax refund totaling A$5,885,131 for the 2025 financial year.
- The refund includes A$104,475 in interest.
- The incentive is part of the Australian Government’s R&D tax program, offering up to a 43.5% refundable tax offset.
- The funds will support the continued development of the company's radiopharmaceutical product portfolio.
Price Impact
More from RADX